Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

22 Feb 2022

Abstract excerpt

BACKGROUND: Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit. We aimed to identify the mechanism(s) underlying PM resistance to oxaliplatin and to develop strategies overcoming such resistance. EXPERIMENTAL DESIGN: We generated a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35194192
DOI: 10.1038/s41416-022-01742-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacityPMID 35194192Read ↗

Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity Read ↗

Loss of <i>UBP1</i> drives oxaliplatin resistance through a targetable dependency on translation initiationSemantic proximity Read ↗

Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistanceSemantic proximity Read ↗

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.Semantic proximity Read ↗

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated stateSemantic proximity Read ↗

Modelling oxaliplatin resistance in colorectal cancer reveals a <i>SERPINE1</i> -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypeSemantic proximity Read ↗

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypeSemantic proximity Read ↗

The cellular pharmacology of oxaliplatin resistanceSemantic proximity Read ↗

“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”Semantic proximity Read ↗

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.Semantic proximity Read ↗

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.